Unum raises $65 million in series B

Unum Therapeutics Inc. (Cambridge, Mass.) raised $65 million in a series B round led by new investor New Leaf Venture Partners. New investors Brace Pharma Capital; Cowen Private Investments; Jennison Associates; Novo A/S; Sabby Management; Sectoral Asset Management; and Wellington Management also participated, as did existing investors Fidelity Biosciences; Atlas Venture; and Sanofi-Genzyme BioVentures.

Seattle Genetics Inc. (NASDAQ:SGEN), which announced a research collaboration with Unum on Monday, invested $5 million (see BioCentury Extra, June 8). ...